Tranexamic Acid Does Not Influence Cardioprotection by Ischemic Preconditioning and Remote Ischemic Preconditioning

Area of Science:

• Cardiovascular Science
• Pharmacology
• Ischemia-Reperfusion Research

Background:

• Aprotinin, an antifibrinolytic, was previously shown to increase infarct size and reduce ischemic preconditioning (IPC) benefits.
• Tranexamic acid (TXA) has replaced aprotinin in clinical use.
• The impact of TXA on ischemia-reperfusion (I/R) injury and cardioprotection from IPC and remote ischemic preconditioning (RIPC) remains unclear.

Purpose of the Study:

• To investigate the effects of TXA on I/R injury.
• To determine if TXA influences cardioprotection mediated by IPC and RIPC.

Main Methods:

• Male Wistar rats were subjected to I/R injury and randomized into six groups.
• Treatments included control, TXA alone, IPC, RIPC, and combinations of TXA with IPC or RIPC.
• Infarct size was assessed to evaluate I/R injury and cardioprotective effects.

Main Results:

• IPC significantly reduced infarct size by 46% (30% ± 6%) compared to controls (56% ± 11%).
• RIPC significantly reduced infarct size by 29% (40% ± 8%) compared to controls.
• Administration of TXA did not alter I/R injury or the infarct size reduction achieved by IPC or RIPC.

Conclusions:

• TXA does not abolish the infarct size reduction provided by IPC.
• TXA does not abolish the infarct size reduction provided by RIPC.
• TXA appears safe concerning I/R injury and does not interfere with established cardioprotective preconditioning strategies.